在1961例肥胖或超重成人中，每周1次皮下注射司美鲁肽2.4 mg与每周1次安慰剂做比较，持续68周后安全性和有效性有何差异。

结果显示，意向性治疗患者接受司美鲁肽治疗68周后，体重下降16.9%。

可以理解为：司美格鲁肽（皮下注射）在减轻体重方面，在同类型的GLP-1类药物中的“疗效”是最好的。

欧洲的医学专家也做过实验比对，司美格鲁肽组的平均体重变化为-15.3kg（-14.9%），而安慰剂组为-2.6kg（-2.4%）。司美格鲁肽组减重超过5%、超过10%、超过15%的比例也非常高。

[1]Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial[J] . Wadden Thomas A.,Bailey Timothy S.,Billings Liana K.,Davies Melanie,Frias Juan P.,Koroleva Anna,Lingvay Ildiko,Oa??Neil Patrick M.,Rubino Domenica M.,Skovgaard Dorthe,Wallenstein Signe O. R.,Garvey W. Timothy,STEP 3 Investigators.  JAMA . 2021

[2]Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial[J] . Rubino Domenica,Abrahamsson Niclas,Davies Melanie,Hesse Dan,Greenway Frank L.,Jensen Camilla,Lingvay Ildiko,Mosenzon Ofri,Rosenstock Julio,Rubio Miguel A.,Rudofsky Gottfried,Tadayon Sayeh,Wadden Thomas A.,Dicker Dror,STEP 4 Investigators.  JAMA . 2021

[3]Time for a new obesity narrative[J] . Johanna Ralston,Hannah Brinsden,Kent Buse,Vanessa Candeias,Ian Caterson,Trevor Hassell,Shiriki Kumanyika,Patricia Nece,Sania Nishtar,Ian Patton,Joseph Proietto,Ximena Ramos Salas,Srinath Reddy,Donna Ryan,Arya M Sharma,Boyd Swinburn,John Wilding,Euan Woodward.  The Lancet . 2018 (1015)

 [4]Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes （SUSTAIN 3）: A 56-Week, Open-Label, Randomized Clinical Trial.[J] . Ahmann Andrew J,Capehorn Matthew,Charpentier Guillaume,Dotta Francesco,Henkel Elena,Lingvay Ildiko,Holst Anders G,Annett Miriam P,Aroda Vanita